tiprankstipranks

NeuroPace Reports Strong Q1 2025 Revenue Growth

NeuroPace Reports Strong Q1 2025 Revenue Growth

Neuropace, Inc. ( (NPCE) ) has released its Q1 earnings. Here is a breakdown of the information Neuropace, Inc. presented to its investors.

Confident Investing Starts Here:

NeuroPace, Inc., based in Mountain View, California, is a medical device company specializing in innovative treatments for epilepsy, notably through its RNS System, a brain-responsive platform designed to reduce seizures in patients with drug-resistant epilepsy.

In its first quarter of 2025, NeuroPace reported a record revenue of $22.5 million, marking a 24% increase from the previous year, driven by growing demand for its RNS System. The company also raised its full-year revenue guidance to between $93 million and $97 million.

Key financial highlights include a 26% year-over-year growth in RNS System revenue, a strong gross margin of 77%, and a reduction in net loss to $6.6 million from $8.9 million in the prior year. NeuroPace also announced a strategic shift to focus on its core RNS System product line, ceasing its distribution of SEEG products by early 2026.

Looking ahead, NeuroPace aims to expand its market reach by targeting new patient populations and advancing its product development, including AI-powered software. The management remains optimistic about sustaining revenue growth and enhancing long-term value creation.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1